Relevant Articles About Acute Lymphoblastic Leukemia (ALL)
Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
KEY TAKEAWAYS The study aimed to investigate the prevalence and outcomes of pathogenic BRCA1/2 variants in patients with early-stage BC. Researchers noticed that similar survival outcomes among gBRCAm and gBRCAwt patients indicate a need for broader screening...
KEY TAKEAWAYS The study aimed to investigate the role of m6A-modified lncRNAs in ferroptosis and cuproptosis during EC progression. Researchers noted that 5 hub lncRNAs could serve as potential biomarkers for targeted therapy and prognosis in EC. Endometrial cancer...
KEY TAKEAWAYS The study performed an exploratory biomarker analysis of immunophenotyping data from the ARTISTRY-1 clinical trial. The analysis suggests NK cell expansion as a potential predictive biomarker for nemvaleukin response in melanoma, requiring further...
The phase 1 study assessed the responses of HuCART19-IL18 in patients with R/R NHL who have previously failed anti-CD19 CART therapy. The trial …
Background In this open-label, randomized, non-comparative, multicenter phase II study (Alliance A091401) we report on three expansion cohorts treated with nivolumab (N) with and without ipilimumab (N+I) and provide a multi-omic correlative analysis of actionable biomarkers. Methods Patients …
Background Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein/ligand 1 (PD-1/PD-L1) are approved for treatment of multiple cancer types. Chemotherapy is often administered with immune checkpoint blockade …
Background The development and progression of colorectal cancer (CRC) are influenced by the gut environment, much of which is modulated by microbial-derived metabolites. Although some research has been conducted on the gut microbiota, there have been …
Background Dual inhibition using anti-programmed death-1 (PD-1) and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) checkpoint inhibitors has proven effective in many cancers. However, its efficacy in rare solid cancers remains unclear. Desmoid tumors are ultrarare soft-tissue tumors, traditionally …